重新回顾seletracetam:一个错失了有效治疗的机会
Wolfgang Löscher1,2, Chris Rundfeldt3, Eugen Trinka3,4,5,6
1Translational Epilepsy Research Group, NIFE, Department of Experimental Otology of the ENT Clinics, Hannover Medical School, Hannover, Germany. Loescher.Wolfgang@mh-hannover.de.
CNS drugs
|March 3, 2026
概括
选择 (SEL) 是一种强效的抗发作药物,在急性发作救援治疗方面表现有前途. 它的新鼻腔配方为患者提供了非二替代品,并提高了患者的安全性和疗效.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 的研究研究.
背景情况:
- 选择 (SEL) 是第二代racetam衍生品,其优化用于突触囊泡糖蛋白2A (SV2A) 的结合.
- 在临床前模型中,SEL表现出强大的抑制作用,具有良好的中枢神经系统耐受性.
- 之前的口服配方已达到IIa期试验,但已停止;其专利于2021年到期.
研究的目的:
- 审查口服SEL的药理学和临床概况.
- 描述一种用于急性发作救援的新型鼻内SEL配方的开发.
- 评估SEL作为一种潜在的非二胺 (非BDZ) 救援治疗急性重复性发作.
主要方法:
- 对抗发作抑制和中枢神经系统耐受性的临床前数据的审查.
- 分析I期和IIa期临床试验数据,用于SEL口服.
- 对鼻内SEL配方的开发和初步人类数据的描述.
主要成果:
- 口服SEL表现出高生物可用性 (>90%),线性药理动力学和约8小时的半衰期.
- 第二阶段a试验表明,SEL在光敏感和焦点中具有有效性和良好的安全性.
- 鼻内SEL配方利用高强度和水溶性用于潜在的急性救援疗法.
结论:
- 在急性发作救援方面,塞莱特拉对类药物具有显著的优势,包括中度镇静,没有呼吸抑制或成潜力.
- 这种新的SEL鼻内制剂,在先前的临床数据的支持下,有可能成为第一个非BDZ急性救援疗法.
- 作为一种新的化学实体 (NCE),SEL为快速发作终止 (REST) 提供了一个有前途的治疗选择.
相关概念视频
Epilepsy and Seizures: Overview
1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.7K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
Antiepileptic Drugs: Glutamate Antagonists
1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Antiepileptic Drugs: Potassium Channel Activators
1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Electroconvulsive Therapy
2.6K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.6K


